Friday, April 07, 2017 5:26:25 AM
HUGE...
GLTA!
U.S. FDA Approves Increased Compassionate Use Patient Cases and Sites for ReCell® in Life-Threatening Injuries
Now allows up to 68 patients to be treated at 18 US burns centers
VALENCIA, Calif. & PERTH, Australia & LONDON--(BUSINESS WIRE)-- The U.S. Food and Drug Administration has approved a further increase in the number of patients who can be treated in the United States with the ReCell® regenerative medical device under a compassionate use protocol, Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY) said today.
The regenerative medicine company, which specializes in the treatment of wounds and skin defects, said the FDA had approved its fourth and largest expansion of its Compassionate Use Investigational Device Exemption (IDE) program for ReCell®, now allowing treatment of up to 68 patients who have insufficient healthy skin available for standard skin grafting treatment of their injury. The FDA also approved an increase to the total number of hospitals that could deploy the protocol from 15 to 18, enabling other hospitals not already involved in the ongoing Continued Access protocol to be introduced to Avita’s autologous cell harvesting approach in cases where the patients’ treating physicians believe there to be no suitable alternative treatment.
“We are pleased to receive this compassionate use expansion, which we think underscores both the necessity of our product for treating life-threatening burns, and the growing interest within the U.S. burns community,” said Avita CEO Adam Kelliher. “We look forward to submitting for premarket approval (PMA) of ReCell in coming weeks with the goal of launching the product, if approved, into the broader burns market in 2018.”
The FDA first approved the IDE for up to 12 subjects in life-threatening circumstances in April 2014. Since then, requests have increased from surgeons to access the exemption and treat their patients. In September 2015, the FDA allowed a doubling of the number of patients permitted under the IDE, from 12 to 24 patients. In February of 2016 the FDA approved an increase to the number of patients to 36 and another increase approval was granted again in October 2016 to 48 patients.
To date, 49 compassionate use cases using ReCell® have been conducted at several leading institutions, including Wake Forest Baptist Medical Center, the Arizona Burn Center at Maricopa Medical Center, Walter Reed National Military Medical Center, MedStar Washington Hospital Center, University of California San Diego Health System, Regional Medical Center / University of Tennessee, the U.S. Army Institute for Surgical Research (San Antonio), University of South Alabama, Baton Rouge General Hospital, Riley Hospital for Children (Indianapolis), and Massachusetts General Hospital.
“We are thrilled that the FDA is allowing us to continue to serve severely burned patients through the Compassionate Use program,” said Andrew Quick, Avita’s Senior VP Clinical Development. “This also allows us to further build our collaborations with U.S. surgeons as we develop best practices for treatment of burn injuries in front of our planned launch of ReCell next year.”
Avita is seeking a Pre-Market Approval (PMA) for its ReCell® device, and its fully enrolled clinical trial has involved seven leading US burns centers. The Company expects to submit its clinical and non-clinical data package in mid-2017, with an anticipated FDA approval in the second calendar quarter of 2018.
ABOUT AVITA MEDICAL LIMITED
Avita’s patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patient’s own skin. Our medical devices work by preparing a Regenerative Epithelial Suspension (RES™), an autologous suspension comprised of the patients’ own skin cells and wound healing factors that are necessary to regenerate natural healthy skin. This is then applied to the area to be treated.
In all countries outside of Europe, our portfolio is marketed under the ReCell® brand to promote skin healing in a wide range of applications including burns, chronic wounds and aesthetics.
ReCell® is TGA-registered in Australia, and CFDA-cleared in China. In the United States, ReCell® is an investigational device limited by federal law to investigational and compassionate use.
In Europe, our portfolio of medical device products received CE-mark approval as three tailored product presentations, with three individual brand names. ReCell® is designed for the treatment of burns and plastic reconstructive procedures; ReGenerCell™ has been formulated for chronic wounds including leg and foot ulcers; and ReNovaCell™ is tailored for aesthetic applications including the restoration of pigmentation.
Recent RCEL News
- AVITA Medical to Announce First Quarter 2024 Financial Results • GlobeNewswire Inc. • 04/15/2024 09:05:00 PM
- AVITA Medical Updates Expected First Quarter 2024 Revenue • GlobeNewswire Inc. • 04/10/2024 09:11:25 PM
- AVITA Medical Submits Response to FDA, Resuming Review Clock for RECELL GO PMA Supplement • GlobeNewswire Inc. • 02/29/2024 09:02:00 PM
- AVITA Medical to Present at TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/29/2024 02:00:00 PM
- AVITA Medical to Host Investor Webinar Briefing • GlobeNewswire Inc. • 02/23/2024 02:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 09:02:06 PM
- AVITA Medical Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance • GlobeNewswire Inc. • 02/22/2024 09:01:00 PM
- AVITA Medical to Announce Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 02/01/2024 09:10:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2024 09:05:12 PM
- AVITA Medical Announces Exclusive Distribution Agreement with Stedical Scientific • GlobeNewswire Inc. • 01/10/2024 09:01:00 PM
- AVITA Medical Announces Preliminary 2023 Financial Highlights, Provides 2024 Financial Guidance and Business Update • GlobeNewswire Inc. • 01/10/2024 02:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 10:51:10 PM
- AVITA Medical to Present at the 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/04/2024 02:00:00 PM
- AVITA Medical to Host Investor Webinar Briefing • GlobeNewswire Inc. • 12/04/2023 02:00:00 PM
- AVITA Medical to Present at the Piper Sandler 35th Annual Healthcare Conference • GlobeNewswire Inc. • 11/21/2023 09:15:00 PM
- Keep An Eye Out: Pre-Market Movers And Analyst Recommendations • IH Market News • 11/21/2023 02:10:28 PM
- AVITA Medical Updates Full Year 2023 Guidance • GlobeNewswire Inc. • 11/20/2023 09:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:09:50 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:07:10 PM
- AVITA Medical Reports Third Quarter Financial Results with 51% Revenue Growth over the Same Period the Prior Year • GlobeNewswire Inc. • 11/09/2023 09:01:00 PM
- AVITA Medical Announces Distribution Partnership with PolyMedics Innovations to Expand to Europe • GlobeNewswire Inc. • 11/09/2023 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/23/2023 08:36:53 PM
- AVITA Medical to Announce Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 10/19/2023 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/18/2023 01:07:51 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM